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Summary
A major obstacle in predicting and preventing the development of
autoimmune type 1 diabetes (T1D) in at-risk individuals is the lack of
well-established early biomarkers indicative of ongoing beta cell stress
during the pre-clinical phase of disease. Recently, serum levels of the a
cytoplasmic isoform of heat-shock protein 90 (hsp90) were shown to be
elevated in individuals with new-onset T1D. We therefore hypothesized
that hsp90a could be released from beta cells in response to cellular stress
and inflammation associated with the earliest stages of T1D. Here, human
beta cell lines and cadaveric islets released hsp90a in response to stress
induced by treatment with a combination of pro-inflammatory cytokines
including interleukin-1b, tumour necrosis factor-a and interferon-c.
Mechanistically, hsp90a release was found to be driven by cytokine-
induced endoplasmic reticulum stress mediated by c-Jun N-terminal
kinase (JNK), a pathway that can eventually lead to beta cell apoptosis.
Cytokine-induced beta cell hsp90a release and JNK activation were signifi-
cantly reduced by pre-treating cells with the endoplasmic reticulum stress-
mitigating chemical chaperone tauroursodeoxycholic acid. The hsp90a
release by cells may therefore be a sensitive indicator of stress during
inflammation and a useful tool in assessing therapeutic mitigation of cyto-
kine-induced cell damage linked to autoimmunity.
Keywords: endoplasmic reticulum stress; heat-shock protein 90; inflam-
mation; Jun N-terminal kinase; type 1 diabetes.
Introduction
Type 1 diabetes (T1D) is a T-cell-mediated autoimmune
disease that results in the targeted destruction of pancre-
atic beta cells. Host immune responses directly targeting
beta cells for destruction in T1D simultaneously promote
beta cell-intrinsic stress responses that accelerate cell
death and loss of insulin production.1 This latent period
of beta cell stress and death has recently been defined as
stage 1 in the three-stage progression to T1D.2 During
this stage, autoimmunity and beta cell loss have begun;
however, sufficient insulin-secreting beta cells remain to
inhibit overt hyperglycaemia and other clinical symptoms.
In some patients, this pre-clinical phase occurs over a
number of months, whereas in others it can last many
years.2,3
Limitations in detecting beta cell stress during this clin-
ically latent stage of T1D constitute a major obstacle in
the implementation of effective disease prevention
strategies.3 Serum levels of the a cytoplasmic isoform of
heat-shock protein 90 (hsp90) were recently shown to be
elevated in individuals with new-onset T1D compared
with control subjects.4 Consistent with this observation,
individuals with T1D had higher levels of circulating
IgG1 and IgG3 class-switched autoantibodies to hsp90.
These antibody isotypes are most commonly produced
Abbreviations: DMOG, dimethyloxaloylglycine; ER, endoplasmic reticulum; HIF-1a, hypoxia inducible factor 1a; hsp, heat-shock
protein; IFN-c, interferon-c; IL-1b, interleukin-1b; iNOS, inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase; MAPK,
mitogen-activated protein kinase; NO, nitric oxide; T1D, type 1 diabetes; TNF-a, tumour necrosis factor-a; TUDCA, taurour-
sodeoxycholic acid; UPR, unfolded protein response
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during T helper type 1-mediated immune responses, the
predominant cell-mediated immune response in T1D.5
Heat-shock protein 90 is a member of the heat-shock
family of molecular chaperones. Within the cell, these
chaperones assist their respective client proteins in folding
and intracellular transport. The hsp90 clients are involved
in cellular processes including signal transduction, protein
trafficking, receptor maturation and immunity.6 The
release of cytosolic hsp90a from certain cell types has
been reported in response to specific stresses.7 Vascular
smooth muscle cells release hsp90a in response to oxida-
tive stress,8 while human fibroblasts release hsp90a in
response to hypoxia and hypoxia inducible factor 1a
(HIF-1a) activation.9 Yet, whether or not hsp90a is
released from pancreatic beta cells in response to cellular
stresses associated with T1D remains untested.
Several markers of stress have been detected in beta
cells during the latent period of T1D. Endoplasmic reticu-
lum (ER) stress precedes the development of T1D in the
non-obese diabetic mouse model,10 and some ER stress
markers are expressed in human islets from individuals
with T1D.11 Before the onset of T1D, beta cells experience
inflammatory stress brought on by insulitis, the infiltra-
tion of immune cells into the pancreatic islets of Langer-
hans. During insulitis, activated macrophages, natural
killer cells, and T cells secrete pro-inflammatory cytokines
such as interleukin-1b (IL-1b), tumour necrosis factor-a
(TNF-a) and interferon-c (IFN-c) that promote beta cell
dysfunction and death.12–14 Beta cells are also sensitive to
reactive oxygen species-mediated oxidative stress, which
can result from glucotoxicity.15
Here, human beta cell lines and cadaveric islets released
elevated levels of hsp90a in response to a combination of
pro-inflammatory cytokines, IL-1b, TNF-a and IFN-c.
Release of hsp90a was not linked to cellular inducible nitric
oxide synthase (iNOS) or HIF-1a activity. Rather, ER stress
mediated by c-Jun N-terminal kinase (JNK) appeared to
play a key role in hsp90a release. Beta cell hsp90a release
was attenuated by pre-treatment with tauroursodeoxycholic
acid (TUDCA), which protects human beta cells against
JNK-mediated, pro-inflammatory cytokine-induced
apoptosis.16 TUDCA treatment reduced beta cell JNK phos-
phorylation in response to cytokine stress. Pharmacological
inhibition and small interfering RNA (siRNA)-mediated
knockdown of JNK attenuated hsp90a release in response
to cytokine stress. Although p38 mitogen-activated protein
kinase (MAPK) was also activated by cytokine stress, inhi-
bition of this kinase did not impact cellular hsp90a release.
Hence, studies here provide mechanistic evidence support-
ing a role for extracellular hsp90a as a non-invasive marker
of human beta cell stress in response to inflammation,
which may be useful in gauging therapeutic interventions
to mitigate stress in these cells.
Materials and methods
Cell culture
The human beta cell lines bLox5 and 1.1B4 17 were kindly
provided by Dr Clayton E. Mathews (University of Florida)
and cultured as described elsewhere.18,19 Human cadaveric
islets were obtained from the Integrated Islet Distribution
Program (City of Hope). Donors were adults ranging 28–
48 years of age with no history of type 2 diabetes (Table 1).
Intact islets were maintained in Connaught Medical
Research Laboratories 1066 media (Gibco, Grand Island,
NY) with 10% fetal bovine serum (HyClone, Logan, UT),
50 U/ml penicillin and 50 lg/ml streptomycin (Corning,
Corning, NY), and 2 mM L-glutamine (Corning).
Stress induction
For stress induction, human bLox5 and 1.1B4 cells were
cultured at 90% confluency and cadaveric islets at a den-
sity of 133 islets/ml. As a control, cells were treated with
media. For classical ER stress, cells were treated with
01 lM thapsigargin (Cayman, Ann Arbor, MI), an inhibi-
tor of sarcoendoplasmic reticulum Ca2+ ATPases, for
24 hr at 37°. To induce inflammatory stress, cells were
treated with 5 ng/ml human recombinant IL-1b (eBio-
science, San Diego, CA), 10 ng/ml human recombinant
TNF-a (PeproTech, Rocky Hill, NJ), and 100 ng/ml
Table 1. Human islet donor profiles
UNOS ID No. Sex Age BMI Race
Islet
purity (%)
Islet
viability (%) Experimental use of islets
AAJY035 M 40 3891 Caucasian 95 99 ELISA, qRT-PCR
AAKE155 M 36 338 Caucasian 95 95 ELISA, Viability, qRT-PCR
ABAF490 F 39 452 Caucasian 80 98 ELISA, Viability, qRT-PCR
ABDT221 M 28 229 Caucasian 85 94 ELISA, Viability
ABEF251 M 48 312 Caucasian 90 95 ELISA, Viability, qRT-PCR
The United Network for Organ Sharing (UNOS) identification number is specified for each organ donor. Organ donors were characterized by
sex, age, body mass index (BMI), and race. Percentages indicate the purity and viability of cells in human islet preparations. The specific experi-
mental use of islets is indicated for each donor.
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human recombinant IFN-c (PeproTech). To examine glu-
cotoxicity, cells were treated with medium with a final D-
glucose (Sigma-Aldrich, St Louis, MO) concentration of
333 mM. Cell viability and plasma membrane integrity
were determined during stress and other treatments by
trypan blue exclusion and a lactate dehydrogenase cyto-
toxicity assay kit (Pierce, Waltham, MA).
Stress mitigating agents
bLox5 cells were treated with pharmacological agents for
6 hr before 24 hr pro-inflammatory cytokine exposure.
Optimal drug concentrations were selected based on cell
viability and drug efficacy. Cells were treated with 100 lM
1400W (Cayman) to inhibit iNOS activity, 10 nM cheto-
min (Cayman) to inhibit HIF-1a activity, 100 lM
dimethyloxaloylglycine (DMOG) (Sigma-Aldrich) to sta-
bilize HIF-1a, 02 and 1 mM TUDCA (Millipore, Billier-
ica, MA) to mitigate ER stress, 10 lM SP600125 (Santa
Cruz Biotechnology, Inc., Dallas, TX) to inhibit JNK sig-
nalling, or 5 and 10 lM SB202190 (Sigma-Aldrich) to
inhibit p38 MAPK activation.
ELISA
An ELISA kit for human hsp90a (Enzo, Exeter, UK) was
used per manufacturer’s instructions. To detect hsp90a in
exosomes, vesicles were isolated from cytokine stressed
beta cells using the ExoQuick-TC kit (Systems Bio-
sciences, Palo Alto, CA) per the manufacturer’s instruc-
tions. Levels of hsp90a were detected in exosomes and
non-exosomal fractions of spent beta cell media by
ELISA. Interleukin-6 levels were quantified by ELISA
using anti-human IL-6 capture and biotin-conjugated
antibodies (Invitrogen, Carlsbad, CA).
Immunoblotting
Cell lysates were prepared in 10 mM Tris–HCl pH 68,
150 mM NaCl and 1% Triton-X 100 with protease
(Sigma-Aldrich) and phosphatase (Cell Signaling Tech-
nology, Danvers, MA) inhibitors. Lysates (20–80 lg of
protein per lane) were resolved by SDS–PAGE and
immunoblotted for protein detection.20
Antibodies
Antibodies to hsp90a were purchased from Enzo (9D2),
while antibodies to phospho-SAPK/JNK (Thr183/Tyr185)
(81E11), total SAPK/JNK (rabbit polyclonal), phospho-p38
MAPK (Thr180/Tyr182) (D3F9), or total p39 MAPK (rab-
bit polyclonal) were purchased from Cell Signaling Tech-
nology. Actin antibody was from Thermo Fisher Scientific
(Waltham, MA) (ACTN05), and GAPDH antibody was
obtained from Millipore (6C5). For immunoblots, primary
antibodies were detected via peroxidase-conjugated Affini-
Pure F(ab’)2 fragment goat anti-mouse, anti-rabbit, or
anti-rat IgG (H+L) (Jackson ImmunoResearch Laborato-
ries, Inc., Bar Harbor, ME).
Quantitative RT-PCR
Total cellular RNA was isolated using an RNeasy Mini
Kit (Qiagen, Hilden, Germany), and cDNA was synthe-
sized using a High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA) per manufac-
turers’ protocols. Amplification of cDNA was achieved by
quantitative RT-PCR using the 7500 Fast Real-Time PCR
System (Applied Biosystems). Commercial TaqMan gene
expression assays were used to detect human ATF3,
ATF4, B2M, DDIT3, GAPDH, HIF1A, HSPA5, HSP90B1,
IL6, NOS2, and VEGFA, while a custom assay for human
XBP1s was used to detect this transcript (Forward primer:
50 CCTGGTTGCTGAAGAGGAG 30, reverse primer: 50
AGTCAATACCGCCAGAATCC 30, and probe: 50
CCTGCACCTGCTGCGGACTC 30) (Applied Biosystems).
Gene expression was presented as target mRNA levels
detected relative to GAPDH levels (delta CT method).
siRNA transfection
bLox5 cells were grown in antibiotic-free medium and
transfected with 100 nM SignalSilence non-targeted con-
trol or SAPK/JNK siRNA (Cell Signaling Technology) for
72 hr using Lipofectamine 2000 (Invitrogen). Protein
knockdown was confirmed by immunoblotting.
Statistics
For comparisons between two groups, statistical signifi-
cance was determined using a two-tailed, unpaired t test.
For quantitative RT-PCR experiments in which two treat-
ments were tested on samples from the same human
donor, a two-tailed, ratio paired t-test was used. To deter-
mine statistical significance among three or more groups,
a one-way analysis of variance was used with Dunnett’s
test to correct for multiple comparisons, each experimen-
tal mean being compared with the control mean. In exper-
iments with two independent variables, statistical
significance was determined using a two-way analysis of
variance with Tukey’s test to correct for multiple compar-
isons between groups. A P-value < 005 was considered
statistically significant. Statistics were calculated using
PRISM 604 (GraphPad Software, Inc., San Diego, CA).
Results
Beta cell hsp90a release in response to stress
Beta cell stress is a major factor contributing to the devel-
opment of T1D, compromising the integrity of pancreatic
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islets and often leading to beta cell loss during the latent
period of disease. To test whether overt stress could pro-
mote hsp90a release from human pancreatic beta cells,
bLox5 and 1.1B4 cells were exposed to several agents
known to induce established cellular stress pathways
including thapsigargin, pro-inflammatory cytokines, and
culture media containing 333 mM glucose. Interestingly,
both bLox5 and 1.1B4 cells released hsp90a in response
to cytokine stress but not with exposure to thapsigargin
or high glucose (Fig. 1a,b). Moreover, human cadaveric
islets also released hsp90a in response to cytokine stress
(Fig. 1c). These results suggest that hsp90a may be
released from human beta cells in response to inflamma-
tory stress. Assays to detect changes in cell viability and
plasma membrane integrity indicated that hsp90a was not
passively released as a result of cell death at 24 hr
(Fig. 1d–g).
Synergistic effects of cytokines on beta cell hsp90a
release
In studies with human islets, full induction of beta cell
stress requires exposure to IL-1b, TNF-a and IFN-c in
concert.21 To determine if IL-1b, TNF-a or IFN-c alone
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Figure 1. Heat-shock protein 90a (hsp90a) was released by human beta cells in response to cytokine stress. Human beta cell lines bLox5 (a) and
1.1B4 (b) were treated for 24 hr with media alone (Ctrl); thapsigargin (Tg); interleukin 1b (IL-1b), tumour necrosis factor-a (TNF-a), and inter-
feron-c (IFN-c (Cyt); or culture media containing 333 mM glucose (Glc), while primary human islets were treated 24 hr with pro-inflammatory
cytokines only (c). Extracellular hsp90a released into the culture media was detected by ELISA. Data for extracellular hsp90a release are presented
as relative to cells cultured under control conditions. Hsp90a values were detected between 07–49 ng/ml for bLox5, 09–64 ng/ml for 11B4,
and 09–201 ng/ml for human islets. Changes in cell viability (%) were determined by trypan blue exclusion for bLox5 cells (d), 11B4 cells (f),
or human cadaveric islets (g). Plasma membrane integrity or leakiness was monitored by detecting cellular release of cytoplasmic lactate dehydro-
genase, and calculated as a relative value comparing cells cultured under control or stress conditions (e). Data are mean + SEM of n = 3 experi-
ments or n = 4 islet donors. *P < 005, **P < 001, ***P < 0001.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 198–210 201
Beta cell stress drives hsp90a release
or in combination was sufficient to promote beta cell
hsp90a release, bLox5 cells were treated with individual
or combinations of cytokines for 24 hr at 37°. Although
IL-1b alone along with combinations of two different
cytokines induced a slight elevation in beta cell hsp90a
release relative to control-treated cells, by far the most
robust release of hsp90a was observed when cells were
treated with all three cytokines (Fig. 2). These results are
consistent with previous studies showing that this combi-
nation of cytokines induces the most stress in human
islets.21
Beta cell hsp90a association with exosomes
Several studies have shown that heat-shock proteins
including hsp90 are associated with extracellular vesicles
known as exosomes.22,23 Here, a small percentage of the
extracellular hsp90a released by cytokine-stressed beta
cells was associated with exosomes, yet most (> 90%) of
the released hsp90a was soluble and not exosome-asso-
ciated (Fig. 3a). Hsp90a and exosome release by beta cells
were detected after 24 hr of cytokine stress, before any
decreases in cell membrane integrity (Fig. 3b). Hsp90a is
abundantly expressed by cells, and intracellular levels of
this chaperone were only marginally altered by cytokine
stress of beta cells. No change in hsp90a protein levels
was observed in cytokine-treated compared with control
bLox5 cells (Fig. 3c,d). Cytokine-treated 1.1B4 cells
exhibited a slight decrease in hsp90a protein levels com-
pared with control cells (Fig. 3e,f).
Beta cell hsp90a release in response to cellular iNOS
activity
Release of hsp90a by vascular smooth muscle cells can be
prompted by oxidative stress,8 and reactive oxygen species
such as nitric oxide (NO) are detected in human islets
exposed to cytokines.24 Furthermore, cytokine-induced
apoptosis of primary rat beta cells and the rat beta cell
line INS-1E is dependent on NO production.25 Cytokine
exposure increased transcript expression for the NO-gen-
erating enzyme iNOS in human bLox5 cells and cadaveric
islets (Fig. 4a,b). To determine if beta cell NO production
was linked to hsp90a release, bLox5 cells were pre-treated
with an iNOS inhibitor 1400W, which blocks cytokine-
induced iNOS production as shown with the rat beta cell
line INS-1.26 Treatment with 1400W failed to affect
hsp90a release by cytokine-stressed beta cells (Fig. 4c),
indicating NO production is not responsible for cellular
hsp90a release.
Beta cell hsp90a release in response to HIF-1a activity
The transcription factor HIF-1a is known to be important
for regulating beta cell function.27 Activation of HIF-1a
has been linked to hsp90a release by fibroblasts during
hypoxia-induced stress associated with wound healing.9
Reactive oxygen species can stabilize HIF-1a even under
normoxic conditions,28 whereas pro-inflammatory cytoki-
nes induce nuclear factor-jB activation leading to
increased HIF-1a gene expression.29 Pro-inflammatory
cytokine treatment prompted increased expression levels
of HIF1A and the HIF-1a target VEGFA in bLox5
(Fig. 5a,b) and islets (Fig. 5c,d), indicating an increase in
HIF-1a activity. bLox5 cells were treated with chetomin,
a HIF-1a inhibitor, before pro-inflammatory cytokine
exposure. This inhibitor promoted even greater hsp90a
release by cytokine-stressed beta cells (Fig. 5e). Moreover,
pre-treating bLox5 cells with DMOG, a prolyl hydroxylase
inhibitor that stabilizes HIF-1a, had no effect on beta cell
hsp90a release in response to cytokines (Fig. 5f). Together
these results suggest that activation of HIF-1a or its
downstream targets, is not responsible for beta cell
hsp90a release upon cytokine stress.
Expression of ER stress markers in cytokine-treated
beta cells
Signature features of ER stress have been detected in the
pancreatic islets of non-obese diabetic mice10 and individ-
uals with T1D.11 Given thapsigargin, an inducer of classi-
cal ER stress, failed to promote beta cell hsp90a release
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Figure 2. Pancreatic beta cells optimally release heat-shock protein
90a (hsp90a) in response to a combination of interleukin-1b (IL-
1b), tumour necrosis factor-a (TNF-a) and interferon-c (IFN-c).
Human bLox5 cells were treated with 5 ng/ml IL-1b, 10 ng/ml TNF-
a and 100 ng/ml IFN-c alone or in various combinations for 24 hr
at 37°. Media were harvested after incubation, and hsp90a levels
were measured by ELISA. Data are presented as relative to control
cells without cytokine. Extracellular hsp90a values ranged between
34 and 309 ng/ml. Data are mean + SEM of n = 3 experiments.
**P < 001 one-way analysis of variance with Dunnett’s correction
for multiple comparisons, each mean compared with no cytokine
control.
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(Fig. 1a,b), changes in the ER stress-associated genes
XBP1s, ATF4, ATF3, DDIT3, HSPA5 and HSP90B1 were
compared in human bLox5 cells exposed to thapsigargin
or pro-inflammatory cytokines (Fig. 6a). Beta cell cytokine
treatment resulted in a modest increase in the expression
levels of XBP1s, ATF3 and HSP90B1 relative to control;
however, changes in XBP1s and HSP90B1 were not signifi-
cant when compared with the more robust responses of
thapsigargin-treated cells. HSP90B1 encodes GRP94, an
ER-retained chaperone with structural homology to cyto-
plasmic hsp90a.6 In contrast with thapsigargin, no differ-
ences were observed in expression levels of ATF4, DDIT3
and HSPA5 in cytokine-exposed beta cells. In human islets,
expression levels of ATF3, HSPA5 and HSP90B1 were sig-
nificantly increased in response to cytokine stress (Fig. 6b),
with some variation observed in individual islet donors.
These results suggest that pro-inflammatory cytokines may
induce a mild or non-canonical ER stress in pancreatic beta
cells after 24 hr. Others have shown that some of these
transcripts can be induced to a greater extent in human
pancreatic beta cells after 48 hr of cytokine stress, although
such prolonged treatments are often associated with
reduced beta cell viability.16 In the present study, a signifi-
cant drop in human beta cell viability was not detected
until 48 hr post-cytokine treatment (Fig. 3b). Hence, full
induction of a classical ER stress response in human beta
cells may require prolonged exposure to cytokines. Still
even after 24 hr of cytokine exposure, human beta cells dis-
play signs of a mild or non-canonical ER stress coinciding
with hsp90a release.
Effects of TUDCA on cytokine-induced hsp90a
release and JNK activation in beta cells
TUDCA is a bile acid that functions as a chemical chaper-
one and reduces ER stress.30–32 This compound has potent
anti-apoptotic effects both in vitro and in vivo.32–34
Administration of TUDCA during the pre-diabetic stage of
T1D dramatically reduced diabetes incidence in two mouse
models of disease.35 Pre-treatment of bLox5 cells with
TUDCA substantially inhibited hsp90a release in response
to cytokine stress (Fig. 7a). At higher concentrations,
TUDCA partially blocked up-regulation of the ER stress
marker ATF3 in cytokine-treated cells (Fig. 7b), consistent
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Figure 3. Mechanisms of heat-shock protein 90a (hsp90a) release. Human bLox5 cells were treated with pro-inflammatory cytokines and after
24 hr the extracellular medium was collected and fractionated to separate exosomes and the residual soluble media fraction, for analysis of
hsp90a distribution. Total hsp90a levels in each fraction were determined by ELISA (a). bLox5 cells were treated with or without pro-inflamma-
tory cytokines for various times, and cellular release of cytoplasmic lactate dehydrogenase was monitored for up to 48 hr (b). Human beta cells
bLox5 (c, d) and 1.1B4 (e, f) were treated for 24 hr with media alone (Ctrl) or interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and
interferon-c (IFN-c) (Cyt). Total cell hsp90a and actin protein levels in each sample were assessed by immunoblotting. (c, e) Representative
images of Western blots, (d, f) densitometry results indicating relative cellular hsp90 levels compared with actin expression from n = 3 experi-
ments. Data are mean + SEM of n = 3 experiments. *P < 005, ***P < 0001.
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with TUDCA mitigation of beta cell ER stress. Yet,
TUDCA treatment did not block all pro-inflammatory
cytokine-induced changes in beta cells as shown by the
sustained induction of transcripts for b2-microglobulin
(Fig. 7c). Recent studies with human beta cells have shown
that cytokine-induced apoptosis can be mediated by JNK
activation downstream of the unfolded protein response
(UPR) sensor IRE1, rather than NO production, as has
been reported for rat beta cells. This cytokine-induced
JNK activation could be mitigated by pre-treatment with
TUDCA.16 Hence, levels of JNK phosphorylation were
examined in bLox5 cells when TUDCA pre-treatment was
provided before cytokine exposure. TUDCA treatment of
beta cells inhibited JNK phosphorylation at 30 min
(Fig. 7e,f) and 24 hr (Fig. 7g,h) post-cytokine treatment.
Notably, thapsigargin failed to induce JNK phosphoryla-
tion in human beta cells (Fig. 7d). These results suggest
that mitigating cytokine-induced cell stress with TUDCA
inhibits hsp90a release by pancreatic beta cells, potentially
through alterations in the UPR and JNK activation.
Beta cell hsp90a release in response to JNK activity
To confirm that JNK activation was important in regulat-
ing hsp90a release from cytokine-treated beta cells, bLox5
cells were pre-treated with a JNK inhibitor, SP600125,
before pro-inflammatory cytokine exposure. JNK activa-
tion is required for the synthesis and secretion of cytokines
such as IL-6, and here JNK inhibition was demonstrated
by analysis of beta cell IL-6 production (Fig. 8a). The JNK
inhibitor SP600125 attenuated hsp90a release in response
to cytokine stress, suggesting that JNK activation is, at
least in part, required for hsp90a release in pancreatic beta
cells in response to cytokine stress (Fig. 8b). To further
confirm that beta cell release of hsp90a was mediated by
JNK activity, siRNA-mediated knockdown of JNK was
performed in bLox5 cells. Decreased JNK protein expres-
sion was observed in beta cells transfected with JNK
siRNA relative to cells transfected with control siRNA
(Fig. 8c,d). Here also, hsp90a release in response to cyto-
kine stress was markedly reduced in beta cells transfected
with JNK siRNA relative to cells transfected with control
siRNA (Fig. 8e). Cytokine-induced stress can also trigger
the activation of another cellular kinase, p38 MAP kinase,
which also promotes beta cell IL-6 release. Indeed, beta
cell IL-6 secretion in response to pro-inflammatory cytoki-
nes was in part due to the activation of p38 kinase, as
demonstrated by the reduction in beta cell IL-6 release
upon inclusion of a p38 inhibitor (Fig. 8f). In contrast,
treatment of beta cells with this p38 kinase inhibitor
resulted in greater hsp90a release by bLox5 cells treated
with pro-inflammatory cytokines (Fig. 8g). These results
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Figure 4. Heat-shock protein 90a (hsp90a)
was not released in response to inducible nitric
oxide synthase (iNOS) activity. Human bLox5
(a) and human islets (b) were treated for 24 hr
with media alone (Ctrl) or with interleukin-1b
(IL-1b), tumour necrosis factor-a (TNF-a) and
interferon-c (IFN-c) (Cyt). NOS2 expression
was detected only after cytokine treatment as
measured by quantitative RT-PCR (UD, unde-
tected). Human bLox5 cells were treated for
6 hr at 37° with medium alone or 100 lM
1400W, an iNOS inhibitor, followed by 24 hr
treatment with pro-inflammatory cytokines.
Following these treatments, extracellular
hsp90a levels were detected by ELISA. hsp90a
release by beta cells was increased in response
to cytokine exposure irrespective of iNOS inhi-
bitor addition (c). Data are presented as rela-
tive to control cells cultured without cytokines
or 1400W. Extracellular hsp90a values detected
ranged between 100 and 346 ng/ml. Data are
mean + SEM of n = 3 experiments or
mean  SEM of n = 4 islet donors. *P < 005.
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support a role for JNK, but not p38, activity in promoting
hsp90a release from pancreatic beta cells in response to
cytokine-induced stress.
Discussion
The identification of a panel of accessible biomarkers to
identify patients early during T1D development remains
an important objective on the path to implementing new
disease interventions and therapies. Understanding the
connections between these markers and beta cell stress is
also important as they may reveal new approaches to dis-
ease prediction and prevention. Sustained elevation of
serum pro-insulin and hsp90a were recently detected in
children at the onset and during the honeymoon initia-
tion period of T1D.4 The premature release of pro-insulin
by beta cells suggests defects in protein biosynthesis, post-
translational processing, and sorting associated with beta
cell stress during the earliest stages of T1D. Given these
data, we postulated that elevated levels of serum hsp90a
may also be indicative of beta cell stress associated with
inflammation.
Studies here clearly illustrate that selective release of the
chaperone hsp90a by beta cells coincides with the initia-
tion of other stress-associated changes brought about by
pro-inflammatory cytokine exposure. Beta cell release of
hsp90a was detected 24 hr post-treatment (Fig. 1a–c)
along with mild induction of NOS2 gene expression
(Fig. 4a,b). However, inhibition of iNOS function had no
effect on hsp90a release in response to cytokine stress
(Fig. 4c). Interestingly, recent studies have shown that
iNOS inhibition does not protect human islet cells from
cytokine-induced apoptosis,16 suggesting that this path-
way may not be a major contributor to human beta cell
stress, as had been demonstrated previously with rat beta
cells.25
HIF-1a is a transcription factor that regulates cellular
stress responses to hypoxia and is known to play an
important role in maintaining beta cell function.27 Here
pro-inflammatory cytokine exposure increased gene
expression levels of HIF1A and the HIF target VEGFA in
human bLox5 cells (Fig. 5a,b) and whole islets (Fig. 5c,
d), suggesting that the HIF pathway is also induced in
response to beta cell inflammatory stress. However, this
pathway was found not to contribute to hsp90a release
by beta cells (Fig. 5e,f), contrasting with the pathway for
hsp90a release by human fibroblasts during hypoxia-asso-
ciated stress in wound healing.9
Beta cell hsp90a release in response to pro-inflamma-
tory cytokine exposure did coincide with increases in the
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Figure 5. Heat-shock protein 90a (hsp90a) was not released in response to altered hypoxia inducible factor 1a (HIF-1a) activity. Human bLox5
and islets were treated for 24 hr with media alone (Ctrl) or interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and interferon-c (IFN-c)
(Cyt). Expression levels of HIF1A and VEFGA transcripts were measured in bLox5 (a, b) and islets (c, d) by quantitative RT-PCR. Human bLox5
cells were treated for 6 hr at 37° with media alone, 10 nM chetomin (e), a HIF-1a inhibitor, or 100 lM DMOG (f), a HIF-1a stabilizer, followed
by 24 hr treatment with pro-inflammatory cytokines. Extracellular hsp90a levels were detected by ELISA. Data are presented as relative to control
cells without drug treatment or cytokines. Extracellular hsp90a values ranged between 14 and 465 ng/ml (e) and 30 and 239 ng/ml (f). Data
are mean + SEM of n = 3 or n = 4 experiments or mean  SEM of n = 4 islet donors. *P < 005, **P < 001, ***P < 0001.
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expression levels of certain UPR-associated genes (Fig. 6).
Moreover, pre-treatment with the chemical chaperone
TUDCA inhibited bLox5 cell hsp90a release (Fig. 7a) and
ATF3 (Fig. 7b) up-regulation in response to cytokine
stress, suggesting that hsp90a release from pancreatic beta
cells may be linked to ER stress and induction of the
UPR. However, exposure to thapsigargin, a classical indu-
cer of ER stress, did not promote hsp90a release by beta
cells (Fig. 1a,b) even though marked induction of UPR-
associated genes was observed with this sarcoendoplasmic
reticulum Ca2+ ATPase inhibitor (Fig. 6a). Classically, the
UPR is thought to increase ER protein-folding capacity
by up-regulating expression of ER chaperones, such as
BiP and GRP94, while simultaneously blocking translation
of proteins not involved in alleviating ER stress.36–38
However, recent studies are identifying new roles for the
UPR in regulating a variety of cellular processes, includ-
ing metabolism, inflammation and apoptosis.39 One such
‘non-canonical’ UPR or ER stress pathway is the activa-
tion of JNK.39
In the context of the UPR, JNK activation initiates
inflammatory responses via AP-1 activation and also pro-
motes survival by initiating autophagy. JNK activation
can also induce apoptosis in cells with unsurmountable
levels of ER stress.36,37 Interestingly, recent studies have
shown that pro-inflammatory cytokine-mediated apopto-
sis of human beta cells is facilitated, at least in part, by
activation of JNK and can be inhibited by the chemical
chaperone TUDCA.16 In the current study, beta cell expo-
sure to pro-inflammatory cytokines activated JNK as
detected by phosphorylation, which could be inhibited by
pre-treatment with TUDCA, similarly to hsp90a release
(Fig. 7a,e,f). Supporting this key role for JNK in
sensing beta cell stress, hsp90a release in response to pro-
inflammatory cytokines was also linked to JNK. Both
pharmacological inhibition (Fig. 8b) and siRNA-mediated
knock-down of JNK (Fig. 8e) inhibited hsp90a release
from bLox5 cells in response to pro-inflammatory cyto-
kine exposure, suggesting that hsp90a release was indeed
related to JNK activity. Exposure to thapsigargin did not
induce JNK phosphorylation, consistent with the lack of
hsp90a release in response to this classical inducer of ER
stress (Figs 1a,b, 7d). These results point to a specific role
for cytokine-induced stress in promoting hsp90a release
from cells.
Cellular release of hsp90a has been demonstrated in a
number of studies; however, the underlying molecular
mechanisms remain elusive, as hsp90a does not express
an N-terminal classic secretion signal peptide;40,41 how-
ever, the possibility remains that hsp90a may contain a
cryptic signal sequence that has not yet been identified.
Others have proposed that hsp90a secretion is regulated
by post-translational modifications such as cleavage,
phosphorylation and acetylation.40,41 Several proteins
involved in inflammation, cytoprotection and tissue
repair are released by cells through an unconventional,
rather than ER/Golgi-dependent, release mechanism that
requires cleavage by caspase-1.42 Release of hsp70 from
prostate cancer cells is mediated by a similar mechanism
and is sensitive to weak bases.43 Yet treatment of beta
cells here with weak bases failed to block hsp90a release
(data not shown).
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Figure 6. Pro-inflammatory cytokine treatment induced a mild endoplasmic reticulum (ER) stress response in pancreatic beta cells after 24 hr.
Human bLox5 cells were treated with media alone (Ctrl), thapsigargin (Tg), or interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and
interferon-c (IFN-c) (Cyt) for 24 hr (a). Human islets were treated for 24 hr with pro-inflammatory cytokines only (b). Expression levels of
XBP1s, ATF4, ATF3 and DDIT3, the last of which encodes the CCAAT/enhancer-binding protein homologous protein (CHOP), HSPA5, which
encodes the binding immunoglobulin protein (BiP), and HSP90B1, which encodes the ER chaperone GRP94, were measured by quantitative RT-
PCR. Data represent the mean + SEM of n = 5 experiments or the mean  SEM results from n = 4 islet donors. *P < 005, **P < 001,
***P < 0001, ****P < 00001.
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Several heat-shock proteins including hsp70 and hsp90
are associated with exosomes.22,23 However, analysis of the
hsp90a released by bLox5 cells revealed only about 10% of
the extracellular released chaperone was associated with
exosomes (Fig. 3a). Yet, this does not preclude cellular
release of exosomes as a conduit pathway for extracellular
hsp90a. Given its cytoplasmic localization, hsp90a may
associate loosely with protein ligands on the cytoplasmic
face of exosomal vesicles. Upon vesicle release, hsp90a
may be released as a chaperone from the surface of exo-
somes as ATP concentrations drop, resulting in increased
levels of free hsp90a detected outside the cell. Alterna-
tively, cytoplasmic hsp90a may be packaged or sequestered
from the cytoplasm within autophagosomes or mutivesic-
ular bodies during formation of these organelles, resulting
in the release of hsp90a into the extracellular environment
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Figure 7. Pre-treatment with TUDCA inhibited beta cell heat-shock protein 90a (hsp90a) release, ATF3 up-regulation, and c-Jun N-terminal
kinase (JNK) phosphorylation in response to cytokine stress. Human bLox5 cells were treated with media alone, 02, or 1 mM TUDCA for 6 hr
followed by 24 hr of stimulation with interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and interferon-c (IFN-c) (Cyt). Extracellular
hsp90a release was measured by ELISA and calculated relative to control cells cultured without cytokines or TUDCA (a). Extracellular hsp90a
values ranged between 50 and 205 ng/ml. ATF3 expression levels were measured by quantitative RT-PCR (b). Gene expression levels of B2M,
which encodes b2-microglobulin, a component of the MHC class I, were measured by quantitative RT-PCR (c). For (a–c), data are mean + SEM
of n = 3 experiments. Phospho-JNK, total JNK, and GAPDH levels were examined in bLox5 cells pre-treated with or without TUDCA (TC) for
6 hr followed by 24 hr of thapsigargin (Tg) or pro-inflammatory cytokine (Cyt) exposure (d). Shown is a representative Western blot image from
n = 3 blots. Phospho-JNK and total JNK levels were examined in bLox5 cells pre-treated with or without TUDCA (TC) for 6 hr followed by
30 min (e, f) or 24 hr (g, h) of pro-inflammatory cytokine (Cyt) exposure. JNK and phosphor-JNK migrate as doublets on SDS–PAGE, while
GAPDH protein levels were assessed in samples as a loading control. (e, g) Representative images, (f, h) densitometry results of phospho-JNK to
total JNK ratios in cytokine-treated cells with and without TUDCA pre-treatment for n = 3 or n = 4 blots. *P < 005, **P < 001, ***P < 0001,
****P < 00001.
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upon vesicle fusion with the plasma membrane. hsp90a
has been identified in autophagosomes isolated from sev-
eral types of human cells following starvation stress.44,45
However, more work is undoubtedly needed to under-
stand the specific secretory mechanism by which hsp90a is
released from the cell.
Studies here are the first to demonstrate an association
between cellular hsp90a release and inflammatory stress
responses linked to the eventual apoptosis of human
pancreatic beta cells.16 Given the evidence of beta cell
stress before the onset of T1D in mice and humans, the
current studies are also consistent with the observed ele-
vated serum levels of hsp90a in patients with new-onset
T1D.4 Equally important, the current work establishes
hsp90a as a readily detectable and non-invasive indicator
of beta cell stress, which may be useful in the testing of
pharmacological agents to mitigate beta cell stress in vitro
and in pre-clinical studies.
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Figure 8. Cytokine-induced heat-shock protein 90a (hsp90a) release by pancreatic beta cells was mediated by c-Jun N-terminal kinase (JNK) and
not p38 mitogen-activated protein (MAP) kinase. Human bLox5 cells were treated with media alone or a JNK inhibitor (SP600125) for 6 hr
before 24 hr stimulation with interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and interferon-c (IFN-c) (Cyt). Extracellular IL-6 (a)
and hsp90a (b) levels were measured by ELISA. Extracellular hsp90a levels were calculated relative to hsp90a release by control cells cultured
without SP600125 or cytokines. Extracellular hsp90a values ranged between 68 and 771 ng/ml. Human bLox5 cells were transfected for 72 hr
with control or JNK siRNA. JNK knockdown was assessed by immunoblotting (c, d). Transfected cells were then treated with media alone or IL-
1b, TNF-a, and IFN-c (Cyt) for 24 hr. Extracellular hsp90a levels were analysed by ELISA (e). Data are presented as relative to control siRNA-
transfected cells treated with media alone. Hsp90a values ranged between 131 and 1785 ng/ml. Human bLox5 cells were treated with media
alone or the p38 MAP kinase inhibitor (SB202190) for 6 hr before 24 hr stimulation with IL-1b, TNF-a, and IFN-c (Cyt). Extracellular IL-6 (f)
and hsp90a (g) levels were measured by ELISA. Extracellular hsp90a levels were indicated relative to control cells treated without SB202190 or
cytokines. Extracellular hsp90a values ranged between 28 and 341 ng/ml. Data are mean + SEM of n = 3 or n = 4 experiments. *P < 005,
***P < 0001, ****P < 00001 (NS, not significant).
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